000 03370nam a22004455i 4500
999 _c394447
_d394447
001 394447
003 ES-MaUEC
005 20230102140116.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 221118s2022 sz | s |||| 0|eng d
020 _a9783031063572
024 7 _a10.1007/978-3-031-06357-2
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC281 .C4
_b2022 EB
245 0 0 _aPediatric Cancer Therapeutics Development
_cedited by Jorge DiMartino, Gregory H Reaman, Franklin O Smith
250 _a1st edition 2022
264 1 _aCham
_bSpringer International Publishing,
_c2022
300 _a1 recurso en línea (VI, 181 páginas)
_b21 ilustraciones, 19 ilustraciones a color
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aPediatric Oncology
_x2191-0812
505 0 _aHistory of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino. .
520 _aThis book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.
988 _aSpringer_Medicine_2022
650 7 _2embne
_9157453
_aCáncer en niños
700 1 _aDiMartino, Jorge
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aReaman, Gregory H
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aSmith, Franklin O
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783031063565
776 0 8 _iPrinted edition:
_z9783031063589
776 0 8 _iPrinted edition:
_z9783031063596
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-06357-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b12/2022
_dz
_eh
_zSI